Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Set to Address API, Coronavirus Vaccine Issues in FY2021 Budget
August 28, 2020
- Japan’s 1st Topical Axillary Hyperhidrosis Drug, JT’s HIF-PH Inhibitor Now in Line for September Approval
August 28, 2020
- MHLW Panels Agree to Prioritize Flu Vaccinations for Elderly, and Then HCPs
August 27, 2020
- MHLW to Accept Sakigake Applications All Year Long under Amended PMD Law
August 27, 2020
- MHLW Vows Thorough Post-Approval Safety Follow-Up on COVID-19 Vaccines: Official
August 27, 2020
- MHLW Likely to Secure Largest Volume of Flu Vaccines since Quadrivalent Switch: Kato
August 26, 2020
- Rakuten Medical’s Sakigake-Designated Photoimmunotherapy Up for MHLW Panel Review on Sept.4
August 25, 2020
- MHLW OKs Label Expansions for Keytruda, Imfinzi, Kadcyla
August 24, 2020
- Japan to Look at H1N1 Flu Rules to Consider Indemnity for COVID-19 Vaccine Makers
August 24, 2020
- MHLW Panel to Ask Osaka Univ. Hospital to Quickly Report on Scientific Validity of Paper: Fabricated Data Scandal
August 24, 2020
- Japan Plans to Provide Indemnity to Coronavirus Vaccine Suppliers
August 21, 2020
- No New Concerns Found for Veklury’s Safety, Efficacy at This Point: MHLW Official
August 21, 2020
- Fujifilm’s Avigan COVID-19 Data Won’t Be Fully Ready until 1 Month from Now
August 21, 2020
- Japan Discussing Participation in COVAX Pact: Sr. Health Vice Minister
August 20, 2020
- Baqsimi’s NHI Tag Doubled on Foreign Price Adjustment, Payer Rep Questions Rule
August 20, 2020
- MHLW Panel to Vet Addition of 9-Valent HPV Vaccine into National Program
August 19, 2020
- Komeito Nudges Govt to Join COVAX Pact for Coronavirus Vaccine Procurement
August 19, 2020
- Entresto, Enerzair, 2 More HIF-PH Inhibitors OK'ed for Listing on August 26
August 19, 2020
- 22 Firms Get Approval for Lyrica Generics towards December Listing, Pfizer AG Included
August 18, 2020
- MHLW Grants Orphan Drug Status to Janssen’s Ibrutinib, 6 Other APIs
August 18, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…